KTOS Kratos Defense

Allocation-underwriting status: Primary-source funded-program, capacity and financing check completed through 25 Sep 2026. Valuation reference: $47.02 close on 24 Sep 2026.

KTOS now clears the threshold for a small starter position, but not a full allocation. The reason is the combination of real funded production evidence, ample liquidity and a materially improved expected-return setup after the price reset. The remaining uncertainty is cash conversion and dilution—not access to capital or lack of customer demand.

Funded / production evidence

• ~$400M of new Department of War funding announced in July across hypersonic and other national-security programs; management explicitly said the funding should accelerate organic growth and improve cash receipts / working capital.
• ~$100M sole-source space-domain-awareness production award announced in July.
• ~$35M military-grade hardware production award announced 31 Aug.
• >$20M mobile SATCOM gateway award announced 1 Sep.
• F143 / GEK800: U.S. Air Force EMD contract as second-source JASSM propulsion; successful Sep. 21 ignition keeps the engine on schedule toward production.
• Spartan J85 / JDAM-LR: engine selected for Boeing's program; Kratos has allocated expanded production capacity and ordered long-lead components for a larger 2027 run.
• Valkyrie / jet drones: Oklahoma City expansion adds >100,000 sq. ft.; current output is ~165 high-performance jet drones annually, with added capacity supporting Valkyrie, Firejet and other systems.

Capacity / financing check

• Q2 cash and cash equivalents: $1.438B.
• Long-term debt: $0; undrawn revolver: $300M less a small amount of letters of credit.
• The balance-sheet strength came partly from a Feb. 2026 equity raise: 16.4M shares sold for about $1.35B net proceeds.
• Shares outstanding were roughly 187.7M by 31 Jul 2026 versus ~168.9M at FY2025 year-end, so dilution has been material.
• FY2026 guidance: operating cash flow $30–50M, capex $125–135M, free-cash-flow use $85–105M while factories, engines, drones and working capital scale.

This is acceptable for a starter because the company is not funding the build from a stressed balance sheet and funded awards are accumulating. It is not acceptable for a large position until utilization, margins and FCF demonstrate that the capacity build earns attractive per-share returns.

PowerFund's current 24-month probability-weighted working value remains ~$83/share. At $47.02, that is roughly 33% annualized. The expected-return advantage versus current Defence alternatives is large enough to compensate for higher execution risk at starter size.

Investment case

Kratos is transitioning from an R&D-heavy defence technology company toward a scaled producer of affordable unmanned aircraft, missile/munition propulsion, hypersonic systems, space-domain-awareness systems and other national-security hardware.

> The allocation thesis is now strong enough for a small starter: funded production demand is visible across multiple businesses, the balance sheet can fund the current industrial build, and the valuation offers substantial expected return. The position should remain small until the company proves that internally funded capacity turns into improving margins, free cash flow and per-share value rather than repeated dilution.

Funded-program / capacity map

Capital discipline

The current build is equity-funded and cash-rich, not leverage-funded. That reduces financial-distress risk but shifts the investment question to return on invested capital and dilution. The February equity raise materially increased shares outstanding, so future allocations should be judged on fully diluted per-share economics.

Position-sizing implication

• Starter: justified now around the current ~$47 price if live thesis/price remain intact.
• Second tranche: require funded volume filling engine/drone capacity plus improving EBITDA margin and cash conversion.
• Larger allocation: require normalized positive FCF and evidence that capacity earns attractive returns without another material equity raise.

This directly applies the PowerFund principle: scale capital with expected return and evidence.

• GEK800/F143 progressing from ignition through the current test campaign into production qualification and orders.
• Spartan J85/JDAM-LR and other small-engine programs converting 2027 capacity into funded volume.
• Additional Valkyrie/MUX-TACAIR/CCA funded production awards.
• Funded backlog and book-to-bill remaining >1x while revenue grows high teens or better.
• EBITDA margin expansion as new factories/utilization scale.
• FY2026/2027 investment intensity peaking, followed by improving operating and free cash flow.
• Evidence that 3,000-engine and ~40-Valkyrie capacity plans are backed by durable funded demand.

• Cash conversion remains unproven: FY2026 guidance still implies ~$85–105M of negative FCF despite strong growth.
• Dilution is material: ~16.4M shares were issued in the Feb. 2026 equity raise, and shares outstanding rose materially versus year-end.
• Capacity utilization: factories/working capital are being built ahead of full serial-production visibility; underutilization would destroy returns.
• Program timing: F143/GEK800 remains in EMD/testing rather than full-rate serial production.
• Valkyrie funding visibility: manufacturing capacity and operational progress are real, but the exact funded production curve remains less transparent than some other programs.
• Margin quality: affordable-mass systems must still prove attractive unit economics at scale.
• Procurement risk: funding can be delayed, reprogrammed or spread over longer periods.
• Execution breadth: propulsion, unmanned, hypersonics, space and C5ISR are all scaling simultaneously.
• Equity-financing precedent: the current cash balance reduces near-term risk but management has demonstrated willingness to fund growth through equity issuance.

Warning — freeze additions

• Funded backlog declines materially or book-to-bill stays below 1x while defence demand remains strong.
• Engine/Valkyrie capacity is built without corresponding funded production commitments.
• EBITDA margin fails to improve despite high-teens revenue growth.
• Diluted shares continue rising materially without proportional growth in per-share base-case value.

Reduce / pass

• GEK800/F143 or major Valkyrie/CCA programs slip by >2–3 quarters or lose customer priority.
• Capex + working-capital investment remains structurally elevated into 2028 without normalized positive FCF.
• Major production assets remain underutilized or unit economics prove unattractive.

Invalidate

> Invalidate if Kratos fails to convert funded demand and internally financed capacity into scalable production economics and improving free cash flow per share.

Hard invalidators include loss of a major unmanned/engine production program, repeated technical failure damaging customer confidence, or capital raises that materially erode per-share upside without creating proportional value.

Kratos remains differentiated by the combination of flight-tested lower-cost unmanned systems + internally controlled propulsion + production infrastructure.

• Traditional primes: deeper balance sheets/customer integration but generally slower and higher-cost development models.
• Anduril/private autonomy competitors: faster software/autonomy culture and aggressive CCA positioning.
• Engine suppliers: the GE Aerospace partnership plus Kratos' Spartan manufacturing gives KTOS unusual propulsion leverage for affordable-mass missiles and drones.

The September JDAM-LR and GEK800 evidence strengthens the propulsion moat more than the unmanned thesis. The most valuable proof from here is recurring funded volume and attractive unit economics, not additional demonstrations.

1. Track quarterly conversion of funded awards into revenue, margin and cash receipts, especially the ~$400M funding pool and ~$100M space-domain-awareness award.
2. Quantify F143/GEK800 EMD milestones, production decision timing and likely unit volumes; do not treat 'toward production' as serial volume.
3. Track Spartan J85 2027 production volume and whether JDAM-LR plus other customers fill the planned engine run.
4. Track tactical-drone funded production units relative to the expanded Oklahoma City capacity; distinguish total jet-drone output from Valkyrie-specific volume.
5. Reconcile adjusted EBITDA growth with operating cash flow, capex, working capital and fully diluted share count.
6. Treat another material equity raise before cash conversion improves as a warning requiring re-underwriting.
7. Compare live expected return against AVAV and MRCY before each additional tranche.

Next full review: after Q3 2026 results or earlier on a major Valkyrie/CCA production award, F143 production decision, or material financing event.